Vanda Pharmaceuticals Inc.
VNDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001347178
In the last 90 days, Vanda Pharmaceuticals Inc. insiders filed 1 open-market purchase and 0 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $304.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $220.5M (102.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Feb 13, 2025 | Feb 7, 2024 | Feb 8, 2023 | Feb 23, 2022 |
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Research and development | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M |
| Selling, general and administrative | $238.0M | $146.4M | $112.9M | $136.5M | $124.0M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.33M | $42.2M |
| Income tax | $81.8M | -$4.02M | $3.83M | $5.03M | $9.21M |
| Net income | -$220.5M | -$18.9M | $2.51M | $6.28M | $33.2M |
| EPS, basic | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.60 |
| EPS, diluted | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 |
| Weighted shares, basic | 58.9M | 58.1M | 57.4M | 56.5M | 55.5M |
| Weighted shares, diluted | 58.9M | 58.1M | 57.6M | 57.0M | 56.9M |
| Margins and growth | |||||
| Operating margin | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% |
| Net margin | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% |
| Revenue growth, year over year | +8.7% | +3.2% | −24.3% | −5.3% | +8.3% |
| Net income growth, year over year | – | −853.3% | −60.0% | −81.1% | +42.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Feb 13, 2025 | Feb 7, 2024 | Feb 8, 2023 | Feb 23, 2022 |
| Cash and equivalents | $84.9M | $102.3M | $135.8M | $135.0M | $52.1M |
| Accounts receivable | $54.6M | $47.1M | $34.2M | $33.5M | $32.5M |
| Inventory | $1.85M | $1.73M | $1.36M | $1.19M | $1.02M |
| Total current assets | $347.3M | $438.9M | $432.9M | $519.3M | $478.3M |
| Property, plant and equipment | $2.25M | $2.13M | $2.04M | $2.57M | $3.11M |
| Intangible assets | $117.1M | $114.1M | $121.4M | $18.6M | $20.1M |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M |
| Total current liabilities | $145.2M | $100.0M | $87.7M | $91.4M | $74.4M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M |
| Shareholders' equity | $327.2M | $538.5M | $544.9M | $527.2M | $504.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Feb 13, 2025 | Feb 7, 2024 | Feb 8, 2023 | Feb 23, 2022 |
| Operating cash flow | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M |
| Capital expenditures | $998.0K | $490.0K | $383.0K | $679.0K | $552.0K |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M |
| Stock-based compensation | $9.47M | $12.4M | $14.0M | $16.3M | $15.4M |
| Investing cash flow | $94.9M | -$17.4M | -$12.1M | $49.9M | -$76.7M |
| Financing cash flow | -$2.91M | -$155.0K | $0 | $734.0K | $3.55M |
| Net change in cash | -$17.5M | -$33.5M | $792.0K | $82.9M | -$9.02M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.4% | 6.3% | 7.3% | 6.4% | 5.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 22, 2026 | 60.5M | +2.3% | SEC |
| Jul 30, 2026 | 60.5M | +2.3% | SEC |
| Apr 30, 2026 | 60.1M | +2.0% | SEC |
| Feb 5, 2026 | 59.1M | +1.4% | SEC |
| Oct 23, 2025 | 59.1M | +1.4% | SEC |
| Jul 24, 2025 | 59.1M | +1.4% | SEC |
| May 1, 2025 | 58.9M | +1.3% | SEC |
| Feb 7, 2025 | 58.3M | +1.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.